Literature DB >> 19495571

Can we use statins to prevent stroke in Fabry disease?

J M Politei1.   

Abstract

UNLABELLED: Fabry disease is a rare, X-linked lysosomal storage disease caused by an inborn deficiency of alpha-galactosidase A, which results in the progressive accumulation of globotriaosylceramide and other neutral glycolipids in a range of cells and tissues. In association with the renal and cardiac insufficiency, cerebrovascular complications can result in the death of the patients. Several mechanisms causing vascular damage that leads to the development of deep-white matter lesions have been described. Recent clinical trials strongly suggest that statins protect against stroke by neuroprotective properties or pleiotropic effects. AIM: To evaluate evidence and potential beneficial effects of statins in the vasculopathy of Fabry disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19495571     DOI: 10.1007/s10545-009-1156-2

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  64 in total

Review 1.  Statins and stroke: evidence for cholesterol-independent effects.

Authors:  P Di Napoli; A A Taccardi; M Oliver; R De Caterina
Journal:  Eur Heart J       Date:  2002-12       Impact factor: 29.983

Review 2.  Exciting, radical, suicidal: how brain cells die after stroke.

Authors:  Eng H Lo; Michael A Moskowitz; Thomas P Jacobs
Journal:  Stroke       Date:  2005-01-06       Impact factor: 7.914

Review 3.  Vascular complications of Fabry disease: enzyme replacement and other therapies.

Authors:  D A Hughes; A B Mehta
Journal:  Acta Paediatr Suppl       Date:  2005-03

4.  Atorvastatin suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells.

Authors:  Katharina Schroecksnadel; Barbara Frick; Christiana Winkler; Barbara Wirleitner; Günter Weiss; Dietmar Fuchs
Journal:  Clin Chem Lab Med       Date:  2005       Impact factor: 3.694

5.  Palmitoylation of endothelial nitric oxide synthase is necessary for optimal stimulated release of nitric oxide: implications for caveolae localization.

Authors:  J Liu; G García-Cardeña; W C Sessa
Journal:  Biochemistry       Date:  1996-10-15       Impact factor: 3.162

6.  Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine.

Authors:  Z Huang; P L Huang; J Ma; W Meng; C Ayata; M C Fishman; M A Moskowitz
Journal:  J Cereb Blood Flow Metab       Date:  1996-09       Impact factor: 6.200

7.  Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis.

Authors:  S Colli; S Eligini; M Lalli; M Camera; R Paoletti; E Tremoli
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-02       Impact factor: 8.311

Review 8.  Statins: potent vascular anti-inflammatory agents.

Authors:  J K Liao
Journal:  Int J Clin Pract Suppl       Date:  2004-10

Review 9.  The role of statins in the prevention of ischemic stroke.

Authors:  Bo Ziedén; Anders G Olsson
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

10.  Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase.

Authors:  Z Huang; P L Huang; N Panahian; T Dalkara; M C Fishman; M A Moskowitz
Journal:  Science       Date:  1994-09-23       Impact factor: 47.728

View more
  6 in total

Review 1.  Stroke and Fabry disease.

Authors:  Miguel Viana-Baptista
Journal:  J Neurol       Date:  2011-10-27       Impact factor: 4.849

Review 2.  Fabry's disease: an example of cardiorenal syndrome type 5.

Authors:  Aashish Sharma; Marco Sartori; Jose J Zaragoza; Gianluca Villa; Renhua Lu; Elena Faggiana; Alessandra Brocca; Luca Di Lullo; Sandro Feriozzi; Claudio Ronco
Journal:  Heart Fail Rev       Date:  2015-11       Impact factor: 4.214

Review 3.  Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features.

Authors:  Michela Ranieri; Gloria Bedini; Eugenio Agostino Parati; Anna Bersano
Journal:  Curr Treat Options Neurol       Date:  2016-07       Impact factor: 3.598

Review 4.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

Review 5.  Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel.

Authors:  Alessandro P Burlina; Katherine B Sims; Juan M Politei; Gary J Bennett; Ralf Baron; Claudia Sommer; Anette Torvin Møller; Max J Hilz
Journal:  BMC Neurol       Date:  2011-05-27       Impact factor: 2.474

Review 6.  Current and experimental therapeutics for Fabry disease.

Authors:  Vanessa Castelli; Cosimo Andrea Stamerra; Michele d'Angelo; Annamaria Cimini; Claudio Ferri
Journal:  Clin Genet       Date:  2021-05-25       Impact factor: 4.438

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.